<DOC>
	<DOCNO>NCT00761995</DOCNO>
	<brief_summary>Safety Efficacy Brinzolamide Dosed TID With Dorzolamide Dosed TID Reducing Intraocular Pressure Patients With Open Angle Glaucoma Ocular Hypertension</brief_summary>
	<brief_title>Safety Efficacy Brinzolamide Dosed TID With Dorzolamide Dosed TID Reducing Intraocular Pressure Patients With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Male female 18 year age old , diagnose primary openangle glaucoma ocular hypertension . If child bear potential * Must use reliable mean contraception duration study surgically sterilize . Must negative pregnancy test . Must nonlactating IOP measurement ≥ 24 ≤ 36 mm Hg , least one eye , 9.00 a.m ≥ 21 ≤ 36 mm Hg least one eye ( eye ) 11.00 measurement The IOP criterion meet time point eye Visual Acuity 6/24 good study eye ( ) Gonioscopy angle ≥ 2 study eye ( ) Patients level understand willingness fully comply visit study procedure schedule study site evidence write informed consent Patients one sight eye amblyopia History chronic recurrent uveitis inflammatory eye disease ( e.g . scleritis ) . History ocular infection ( e.g . conjunctivitis ) within past 3 month . History ocular trauma within past 6 month . History severe progressive retinal ( i.e . retinal degeneration , diabetic retinopathy , retinal detachment retinal tear ) optic nerve disease . History severe ocular pathology severe glaucoma damage determine optic nerve head ( e.g . C/D ratio &gt; 0.8 ) visual field evaluation ( e.g . split fixation , clinically significant field loss within central field ) legal blindness either eye . Intraocular surgery within past 12 month Laser surgery within past 3 month determine patient history and/or examination . Any form glaucoma primary open angle glaucoma . Inability discontinue contact lens wear day History hypersensitivity oral topical CAIs , sulfonamide drug component medicine . Any abnormality prevent reliable applanation tonometry either eye . Patients investigator 's best judgement risk visual field visual acuity worsen consequence participation trial . Chronic use systemic medication may effect IOP le one month stable dose regimen ( i.e . sympathomimetic agent , betaadrenergic block agent , alpha agonist , alphaadrenergic block agent , calcium channel blocker , angiotensinconverting enzyme inhibitor , etc. ) . Current use ophthalmic , dermatologic systemic steroid . Patients clinically significant medical ( acute progressive ) condition e.g . cardiovascular , pulmonary , hematologic disease psychiatric illness , unlikely fully complete protocol requirement assess investigator . Participation another clinical trial within past 30 day . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Raised IOP</keyword>
</DOC>